Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 104

1.

Investigating the mechanisms of hallucinogen-induced visions using 3,4-methylenedioxyamphetamine (MDA): a randomized controlled trial in humans.

Baggott MJ, Siegrist JD, Galloway GP, Robertson LC, Coyle JR, Mendelson JE.

PLoS One. 2010 Dec 2;5(12):e14074. doi: 10.1371/journal.pone.0014074.

2.

The neuropharmacology of sleep paralysis hallucinations: serotonin 2A activation and a novel therapeutic drug.

Jalal B.

Psychopharmacology (Berl). 2018 Nov;235(11):3083-3091. doi: 10.1007/s00213-018-5042-1. Epub 2018 Oct 5. Review.

3.

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences.

Carbonaro TM, Johnson MW, Hurwitz E, Griffiths RR.

Psychopharmacology (Berl). 2018 Feb;235(2):521-534. doi: 10.1007/s00213-017-4769-4. Epub 2017 Nov 7.

PMID:
29116367
4.

Serotonergic Hallucinogen-Induced Visual Perceptual Alterations.

Kometer M, Vollenweider FX.

Curr Top Behav Neurosci. 2018;36:257-282. doi: 10.1007/7854_2016_461. Review.

PMID:
27900674
5.

Effect of a hallucinogenic serotonin 5-HT2A receptor agonist on visually guided, hippocampal-dependent spatial cognition in C57BL/6J mice.

Zhang G, Cinalli D, Stackman RW Jr.

Hippocampus. 2017 May;27(5):558-569. doi: 10.1002/hipo.22712. Epub 2017 Mar 2.

PMID:
28176400
6.

Activation of serotonin 2A receptors underlies the psilocybin-induced effects on α oscillations, N170 visual-evoked potentials, and visual hallucinations.

Kometer M, Schmidt A, Jäncke L, Vollenweider FX.

J Neurosci. 2013 Jun 19;33(25):10544-51. doi: 10.1523/JNEUROSCI.3007-12.2013.

7.

Hallucinogens and Serotonin 5-HT2A Receptor-Mediated Signaling Pathways.

López-Giménez JF, González-Maeso J.

Curr Top Behav Neurosci. 2018;36:45-73. doi: 10.1007/7854_2017_478. Review.

8.

Assessment of the MDA and MDMA optical isomers in a stimulant-hallucinogen discrimination.

Baker LE, Taylor MM.

Pharmacol Biochem Behav. 1997 Aug;57(4):737-48.

PMID:
9259001
9.

Comparative behavioural and neurochemical studies with a psychomotor stimulant, an hallucinogen and 3,4-methylenedioxy analogues of amphetamine.

Hegadoren KM, Martin-Iverson MT, Baker GB.

Psychopharmacology (Berl). 1995 Apr;118(3):295-304.

PMID:
7617822
11.

Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinogenic drugs.

Sanders-Bush E, Breeding M.

Psychopharmacology (Berl). 1991;105(3):340-6.

PMID:
1665919
12.

A behavioral comparison of Nexus, cathinone, BDB, and MDA.

Bronson ME, Jiang W, DeRuiter J, Clark CR.

Pharmacol Biochem Behav. 1995 Jun-Jul;51(2-3):473-5.

PMID:
7667371
13.

Hallucinogenic 5-HT2AR agonists LSD and DOI enhance dopamine D2R protomer recognition and signaling of D2-5-HT2A heteroreceptor complexes.

Borroto-Escuela DO, Romero-Fernandez W, Narvaez M, Oflijan J, Agnati LF, Fuxe K.

Biochem Biophys Res Commun. 2014 Jan 3;443(1):278-84. doi: 10.1016/j.bbrc.2013.11.104. Epub 2013 Dec 2.

PMID:
24309097
14.

Cocaine--stimulus generalization to MDA optical isomers: a reevaluation.

Young R, Glennon RA.

Pharmacol Biochem Behav. 1997 May-Jun;57(1-2):115-8.

PMID:
9164561
15.

Role of the 5-HT₂A receptor in the locomotor hyperactivity produced by phenylalkylamine hallucinogens in mice.

Halberstadt AL, Powell SB, Geyer MA.

Neuropharmacology. 2013 Jul;70:218-27. doi: 10.1016/j.neuropharm.2013.01.014. Epub 2013 Jan 29.

16.

Comparing triggers to visual disturbances among individuals with positive vs negative experiences of hallucinogen-persisting perception disorder (HPPD) following LSD use.

Lev-Ran S, Feingold D, Goodman C, Lerner AG.

Am J Addict. 2017 Sep;26(6):568-571. doi: 10.1111/ajad.12577. Epub 2017 Jun 27.

PMID:
28654720
17.

Serotonergic mechanisms of hallucinogenic drug effects.

Heym J, Jacobs BL.

Monogr Neural Sci. 1987;13:55-81. Review. No abstract available.

PMID:
2891030
18.

Receptor pharmacology of MDMA and related hallucinogens.

Teitler M, Leonhardt S, Appel NM, De Souza EB, Glennon RA.

Ann N Y Acad Sci. 1990;600:626-38; discussion 638-9.

PMID:
1979215
19.

Effects of the hallucinogen psilocybin on covert orienting of visual attention in humans.

Gouzoulis-Mayfrank E, Thelen B, Maier S, Heekeren K, Kovar KA, Sass H, Spitzer M.

Neuropsychobiology. 2002;45(4):205-12.

PMID:
12097810
20.

Studies of dioxole ring substituted 3,4-methylenedioxyamphetamine (MDA) analogues.

Nichols DE, Oberlender R, Burris K, Hoffman AJ, Johnson MP.

Pharmacol Biochem Behav. 1989 Nov;34(3):571-6.

PMID:
2623014

Supplemental Content

Support Center